ClinicalTrials.gg
CompletedNCT01936025DXM2Updated Nov 7, 2017

A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test

A Phase 2 interventional study of Dextromethorphan and Sitagliptin in Type 2 Diabetes Mellitus, sponsored by Profil Institut für Stoffwechselforschung GmbH. Completed at 1 site in Germany. Open to male participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-11-07.

Sponsored by Profil Institut für Stoffwechselforschung GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
148th of 197
34 · median 102
Started
2013
with 13 others
Phase 2
10 of 198
none open now
Registered
138th of 198
by date

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 148th largest by enrollment of the 197 interventional ones that give a count, is one of 14 that started in 2013, is one of 10 in phase 2, and was the 138th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 45 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study has a randomized, double-blind, placebo-controlled, double dummy and eight-way cross-over design. Males with T2DM on a stable metformin monotherapy will be screened for participation in the study. Eligible subjects will be randomized to receive DXM 30 mg, DXM 60 mg, DXM 90 mg alone or in combination with sitagliptin 100 mg, sitagliptin 100 mg alone, or placebo (for DXM and sitagliptin) on in total eight treatment days. An OGTT will be started 1 hour after study drug administration and blood glucose will be measured over the next 4 hours. There will be a 3 to 14-day washout period between doses.

Read the detailed description

This study is performed to determine the optimal dose of DXM that, compared to placebo, decreases glucose excursions following an OGTT. Doses of 30 mg, 60 mg and 90 mg DXM were chosen. Since DXM 60 mg was effective in the previous study in increasing insulin secretion, this dose will be kept. A lower dose (30 mg) will be given to see whether effects on insulin secretion are present also at lower doses and then translate into a BG lowering action. A higher dose (90 mg) will be added to see whether this way an effect on glucose excursion reduction occurs following an OGTT, (like previously demonstrated with 270 mg DXM) that can be related to an increase of insulin secretion.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes mellitus
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated written obtained before any study-related activities
  2. Male subjects with a diagnosis of type 2 diabetes mellitus according to ADA criteria at least 4 months prior to screening
  3. Medical history without major pathology (with the exception of type 2 diabetes)
  4. On a stable regimen of metformin monotherapy for at least 3 months
  5. Aged between 45 and 70 years of age, both inclusive
  6. (BMI) between 25 and 35kg/m2, both inclusive

Exclusion criteria

Exclusion Criteria:

  1. Subjects with type 1 diabetes, MODY or secondary forms of diabetes such as due to pancreatitis
  2. History of pancreatitis
  3. Current or previous treatment with insulin therapy
  4. Treatment with any hypoglycemic medication other than metformin within the three months prior to screening
  5. Mean > 450 msec
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    Sitagliptin

    Placebo dextromethorphan + sitagliptin 100 mg

    Drug: Sitagliptin

  • Experimental
    Dextromethorphan 30 mg + sitagliptin

    Dextromethorphan 30 mg + sitagliptin 100 mg

    Drug: Dextromethorphan · Drug: Sitagliptin

  • Experimental
    Dextromethorphan 60 mg + sitagliptin

    Dextromethorphan 60 mg + sitagliptin 100 mg

    Drug: Dextromethorphan · Drug: Sitagliptin

  • Experimental
    Dextromethorphan 90 mg + sitagliptin

    Dextromethorphan 90 mg + sitagliptin 100 mg

    Drug: Dextromethorphan · Drug: Sitagliptin

  • Experimental
    Dextromethorphan 30 mg + placebo

    Dextromethorphan 30 mg + placebo (sitagliptin)

    Drug: Dextromethorphan

  • Experimental
    Dextromethorphan 60 mg + placebo

    Dextromethorphan 60 mg + placebo (sitagliptin)

    Drug: Dextromethorphan

  • Experimental
    Dextromethorphan 90 mg + placebo

    Dextromethorphan 90 mg + placebo (sitagliptin)

    Drug: Dextromethorphan

  • Placebo comparator
    Placebo

    Placebo (dextromethorphan)+ placebo (sitagliptin)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. lowest dose of DXM

    To find the lowest dose of DXM that, compared to placebo, exerts BG lowering effects related to an OGTT

    Time frame: up to 4 hours after study drug administration

Secondary outcomes

  1. additive BG lowering effects

    To demonstrate whether the administration of DXM on top of sitagliptin exerts additive BG lowering effects related to an OGTT as compared to sitagliptin alone and DXM alone

    Time frame: up to 4 hours after study drug administration

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
08

References and documents

Publications

  • Marquard J, Stirban A, Schliess F, Sievers F, Welters A, Otter S, Fischer A, Wnendt S, Meissner T, Heise T, Lammert E. Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial. Diabetes Obes Metab. 2016 Jan;18(1):100-3. doi: 10.1111/dom.12576. Epub 2015 Oct 26. PubMed 26362564 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2013
First posted
Sep 5, 2013
Start
Oct 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
Nov 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01936025
Responsible party
Sponsor
First posted
Sep 5, 2013
Start date
Oct 2013
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Nov 7, 2017

Study contacts

Alin Stirban, MD
principal investigator · Profil Institut für Stoffwechselforschung GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dextromethorphan · Sitagliptin

Start the discussion